Kura Oncology's Ziftomenib Earns FDA Approval, Paving Path for Expanded AML Treatment and FTI Comeback
核心洞察
Kura Oncology's menin (搜索) inhibitor ziftomenib (Komzifti) received FDA approval in November 2025 for AML patients with NPM1 mutations or KMT2A rearrangements.
The San Diego-based biotech, founded in 2014, is now pursuing broader AML indications for ziftomenib to address this notoriously difficult-to-treat cancer.
Kura is also advancing darlifarnib (搜索), a farnesyl transferase (搜索) inhibitor, which the company believes could complement Revolution Medicines' breakthrough RAS inhibitor daraxonrasib.
San Diego-based Kura Oncology has achieved a milestone that few biotech startups ever reach: shepherding a novel cancer drug from discovery through the full R&D gauntlet to FDA approval. In November 2025, the agency approved ziftomenib, branded as Komzifti, an oral menin (搜索) inhibitor for patients with acute myeloid leukemia (搜索) (AML) harboring specific genetic alterations — namely NPM1 mutations or KMT2A rearrangements.
The approval marks the culmination of over a decade of work at Kura, which was founded in 2014 by co-founder and CEO Troy Wilson. Yet the company views this as merely the starting point. Kura now aims to demonstrate that ziftomenib can benefit a broader population of AML patients, a group that has long faced limited treatment options against a notoriously aggressive and difficult-to-treat cancer.
"Not many biotech startup companies make it all the way through the R&D gauntlet to develop an FDA approved medicine," Wilson noted in a recent interview on The Long Run, reflecting on the company's journey from inception to commercialization.
The Menin Mechanism and Initial Approval
Ziftomenib works by inhibiting menin (搜索), a protein that plays a critical role in driving certain genetically defined subsets of AML. The drug's oral formulation offers a convenient administration route for patients, a meaningful advantage in a disease where treatment regimens can be grueling. The initial FDA approval covers patients whose tumors carry NPM1 mutations or KMT2A rearrangements — molecular alterations that define a distinct, albeit relatively small, segment of the AML population.
Expanding the AML Frontier
With the first approval secured, Kura is setting its sights on a larger ambition: proving ziftomenib's utility across a wider swath of AML patients. The company is actively working to generate clinical evidence that could support label expansions, potentially bringing this targeted therapy to more individuals confronting a cancer that has historically frustrated both clinicians and drug developers alike.
A Second Shot: Darlifarnib and the FTI Revival
Beyond ziftomenib, Kura is betting on a second pipeline asset that could reignite interest in a once-abandoned drug class. Darlifarnib (搜索), a farnesyl transferase (搜索) inhibitor (FTI), belongs to a category of medicines that the broader pharmaceutical industry had largely written off as a "pharma graveyard." Kura's scientists, however, see a compelling rationale for resurrection — particularly as FTIs may logically complement the new breakthrough RAS inhibitor daraxonrasib, developed by Revolution Medicines. This combination approach could unlock new therapeutic possibilities in RAS-driven cancers, an area of intense contemporary interest in oncology drug development.
A Track Record of Success
Wilson brings to Kura a distinguished track record in biotech entrepreneurship. Before Kura, he co-founded three companies that each culminated in successful acquisitions: Intellikine, a PI3 kinase inhibitor company acquired by Takeda; Ambrx, a developer of antibody-drug conjugates acquired by Johnson & Johnson; and Avidity Biosciences, a pioneer of antibody oligonucleotide conjugates for rare muscular diseases acquired by Novartis. This pattern of building scientifically rigorous platforms and advancing them to value-inflection points underscores the strategic approach Wilson has brought to Kura Oncology's evolution from startup to commercial-stage company.